Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02985957 · ClinicalTrials.gov registry record · Phase 2
A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
A Phase 2 study of Prostate Cancer, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 351
- Enrollment target
- 20
- Study locations
NCT02985957: Completed Phase 2 study of Prostate Cancer, sponsored by Bristol-Myers Squibb.
NCT02985957 is a Phase 2 study of Prostate Cancer that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 351 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02985957, a Phase 2 study of Prostate Cancer, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 351 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effectiveness, safety and tolerability of nivolumab followed by ipilimumab, in subjects with metastatic castration resistant prostate cancer (mCRPC).
Primary Outcome
Objective response rate (ORR) is defined as the percent of participants who had confirmed complete or partial best overall response (BOR) per retrospective Blinded Independent Central Review (BICR) among treated participants with measurable disease at baseline. For participants without documented progression by RECIST v1.1 or subsequent therapy, all available response assessments contributed to the BOR assessment. Partial Response is at least a 30% decrease in the sum of diameters of target les
Conditions Studied
Interventions
- DRUG Prednisone
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- DRUG Cabazitaxel
Study Locations (20)
New York
- Local Institution - 0078 - Albany
- Local Institution - 0065 - Lake Success
- Local Institution - 0001 - New York
New South Wales
- Local Institution - 0027 - Gosford
- Local Institution - 0059 - Wahroonga
- Local Institution - 0029 - Westmead
Pennsylvania
- Local Institution - 0047 - Allentown
- Local Institution - 0010 - Philadelphia
Texas
- Local Institution - 0079 - Austin
- Local Institution - 0002 - Houston
Queensland
- Local Institution - 0028 - Southport
- Local Institution - 0043 - Woolloongabba
Arizona
- Local Institution - 0074 - Tucson
Georgia
- Local Institution - 0046 - Marietta
Illinois
- Local Institution - 0011 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 351 participants |
| Start Date | 2017-03-26 |
| Est. Completion | 2025-01-07 |
| Phase | Phase 2 |
What the finished NCT02985957 record still lists
NCT02985957 is an interventional study that assigns participants to a tested intervention. The registered 351 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Prednisone is the first listed.
NCT02985957 names 20 study sites across 13 states, led by New York, New South Wales, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02985957 about?
NCT02985957 is a clinical study titled "A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)". The purpose of this study is to evaluate the effectiveness, safety and tolerability of nivolumab followed by ipilimumab, in subjects with metastatic castration resistant prostate cancer (mCRPC).
What is the current status of trial NCT02985957?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 351 participants. The study started on 2017-03-26. Estimated completion is 2025-01-07.
What conditions does trial NCT02985957 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02985957?
The interventions under investigation include: Prednisone (DRUG), Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Cabazitaxel (DRUG).
Who is sponsoring clinical trial NCT02985957?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02985957 being conducted?
This trial has 20 study locations across Arizona, Georgia, Illinois, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02985957's enrollment target sits among peer trials
351 145th of 735 higher than 591 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06241456 · 351 participants · Phase 1
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
- NCT06576726 · 351 participants
Sensorimotor and Psychosocial Trajectories in Adolescents With Tic Disorder
- NCT07043400 · 351 participants · Phase 3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT07261423 · 351 participants · NA
Pollution Intervention to Impact Kids Asthma Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI